- KR₩1tn
- KR₩1tn
- KR₩229bn
- 80
- 11
- 75
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.14 | ||
| PEG Ratio (f) | 0.37 | ||
| EPS Growth (f) | 104.54% | ||
| Dividend Yield (f) | 0.68% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.33 | ||
| Price to Tang. Book | 2.76 | ||
| Price to Free Cashflow | 59.89 | ||
| Price to Sales | 4.76 | ||
| EV to EBITDA | 29.1 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.78% | ||
| Return on Equity | 3.41% | ||
| Operating Margin | 8.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 140,827.51 | 184,869.55 | 195,096.22 | 221,120.68 | 228,621.97 | 283,905 | 331,279 | 2.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +61.29 | -88.02 | +243.64 | +202.24 | +35.15 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Company’s main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
Directors
- Hyeon Ho Jung CEO (57)
- Gi Hyeok Yang VPR (52)
- Hui Seok Joo MDR (55)
- Yeong Yik Cheon OTH (57)
- Michael Lopez OTH (59)
- Seung Beom Park OTH (51)
- Dong Hyeon Yoo NID (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 2nd, 2000
- Public Since
- January 16th, 2009
- No. of Shareholders
- 34,763
- No. of Employees
- 280
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 6,659,428
- Address
- 78, CHEONGJU, 28126
- Web
- https://www.medytox.com/
- Phone
- +82 432171555
- Auditors
- Samil Accounting Corp.
Upcoming Events for 086900
Q2 2025 Medy Tox Inc Earnings Release
Similar to 086900
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
What is the Medy Tox share price?
As of Today at 21:59 UTC, shares in Medy Tox are trading at KR₩163,400. This share price information is delayed by 15 minutes.
How has the Medy Tox share price performed this year?
Shares in Medy Tox last closed at KR₩163,400 and the price had moved by +26.45% over the past 365 days. In terms of relative price strength the Medy Tox share price has outperformed the FTSE Developed Asia Pacific Index by +27.89% over the past year.
What are the analyst and broker recommendations for Medy Tox?
The overall consensus recommendation for Medy Tox is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medy Tox dividend yield?
The Medy Tox dividend yield is 0.67% based on the trailing twelve month period.
Does Medy Tox pay a dividend?
Last year, Medy Tox paid a total dividend of KR₩1,100, and it currently has a trailing dividend yield of 0.67%. We do not have any data on when Medy Tox is to next pay dividends.
When does Medy Tox next pay dividends?
We do not have data on when Medy Tox is to next pay dividends. The historic dividend yield on Medy Tox shares is currently 0.67%.
How do I buy Medy Tox shares?
To buy shares in Medy Tox you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medy Tox?
As of the previous close price of KR₩163,400, shares in Medy Tox had a market capitalisation of KR₩1tn.
Where are Medy Tox shares listed?
Here are the trading details for Medy Tox:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 086900
What kind of share is Medy Tox?
Based on an overall assessment of its quality, value and momentum Medy Tox is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medy Tox share price forecast for 2025?
The analyst consensus target price for shares in Medy Tox is KR₩214,615. That is 31.34% above the last closing price of KR₩163,400.
Analysts covering Medy Tox currently have a consensus Earnings Per Share (EPS) forecast of KR₩7,680 for the next financial year.
Find out moreWhat is the trend in the Medy Tox share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medy Tox. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +1.85%.
As of the last closing price of KR₩163,400, shares in Medy Tox were trading +7.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medy Tox PE Ratio?
The Medy Tox PE ratio based on its reported earnings over the past 12 months is 19.14. The shares last closed at KR₩163,400.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medy Tox?
Medy Tox's management team is headed by:
- Hyeon Ho Jung - CEO
- Gi Hyeok Yang - VPR
- Hui Seok Joo - MDR
- Yeong Yik Cheon - OTH
- Michael Lopez - OTH
- Seung Beom Park - OTH
- Dong Hyeon Yoo - NID